Market Cap 164.62M
Revenue (ttm) 61.86M
Net Income (ttm) -11.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 24.42
Profit Margin -18.48%
Debt to Equity Ratio 0.79
Volume 328,800
Avg Vol 209,328
Day's Range N/A - N/A
Shares Out 33.26M
Stochastic %K 22%
Beta 1.03
Analysts Strong Sell
Price Target $13.25

Company Profile

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 480 434 6670
Address:
9237 East Via de Ventura Blvd., Suite 105, Scottsdale, United States
buymoremakemore
buymoremakemore Apr. 2 at 5:06 AM
$DERM The amount of personal testemonials of rosacea patients seeking closure on rosacea forums like reddit saying “I tried doxy/oracea, but…” and “then I tried emrosi and it works great with no issues” is staggering. When we are on more formularies this is going to matter because there is no guarantee we will get immediate coverage or prior authorization before coverage. Often times there are multiple steps before coverage like single step therapy, which means people have to try a lower cost drug like doxycycline generic before getting covered for Emrosi. Some formularies might be jerks and say “try generic doxycycline and generic minocycline before we cover emrosi”. But I think that will be much less common. Single step therapy and prior authorization will probably be what you find on most formularies very very soon. So yeah, keep the “I tried doxy/oracea, but…” people coming!!! All people want is to have better skin. There are people who are scared and unhappy with the way they look just looking for a solution. Emrosi is that solution, and insurance companies will find that soon enough. Well before 2039. Likely in the next year. Great risk reward for those willing to wait.
0 · Reply
gb11
gb11 Apr. 1 at 8:10 PM
$DERM $5 mark is rejected violently with low volume. Brutal. Shorts in full control.
0 · Reply
buymoremakemore
buymoremakemore Apr. 1 at 6:22 PM
$FBIO $DERM thank god. FinSun finally blocked me. Such a loser. Couldn’t even prove he made over 100k shorting these stocks
0 · Reply
FinSUN
FinSUN Apr. 1 at 6:09 PM
$DERM lets go to 4 now
0 · Reply
gb11
gb11 Mar. 31 at 8:05 PM
$DERM performed better today than $FBIO. But I wouldn't expect a recovery for $DERM until we close above 5.
0 · Reply
stklover
stklover Mar. 31 at 2:17 PM
$DERM After getting cloberred, my “3-day rule” applies, so I doubled my position on the stock this AM. I’m patient on this pig. Hoping some company just buys them out in the next year.
0 · Reply
FinSUN
FinSUN Mar. 31 at 11:04 AM
0 · Reply
pandodark
pandodark Mar. 31 at 3:51 AM
$DERM Management’s a joke. They probably won’t even issue news until it’s $2. Honestly, they are too old to see how the news and social cycle affects share price. They cost investors so much money …
0 · Reply
FinSUN
FinSUN Mar. 30 at 8:25 PM
1 · Reply
gb11
gb11 Mar. 30 at 8:23 PM
$DERM will the good new for $FBIO help this stock SP?
0 · Reply
Latest News on DERM
Journey Medical: Emrosi Is Winning, But The Stock Hasn't Noticed

Jan 22, 2026, 8:43 PM EST - 2 months ago

Journey Medical: Emrosi Is Winning, But The Stock Hasn't Noticed


Top 3 Health Care Stocks That May Crash In Q2

Apr 7, 2025, 11:23 AM EDT - 1 year ago

Top 3 Health Care Stocks That May Crash In Q2

ALMS CMRX


buymoremakemore
buymoremakemore Apr. 2 at 5:06 AM
$DERM The amount of personal testemonials of rosacea patients seeking closure on rosacea forums like reddit saying “I tried doxy/oracea, but…” and “then I tried emrosi and it works great with no issues” is staggering. When we are on more formularies this is going to matter because there is no guarantee we will get immediate coverage or prior authorization before coverage. Often times there are multiple steps before coverage like single step therapy, which means people have to try a lower cost drug like doxycycline generic before getting covered for Emrosi. Some formularies might be jerks and say “try generic doxycycline and generic minocycline before we cover emrosi”. But I think that will be much less common. Single step therapy and prior authorization will probably be what you find on most formularies very very soon. So yeah, keep the “I tried doxy/oracea, but…” people coming!!! All people want is to have better skin. There are people who are scared and unhappy with the way they look just looking for a solution. Emrosi is that solution, and insurance companies will find that soon enough. Well before 2039. Likely in the next year. Great risk reward for those willing to wait.
0 · Reply
gb11
gb11 Apr. 1 at 8:10 PM
$DERM $5 mark is rejected violently with low volume. Brutal. Shorts in full control.
0 · Reply
buymoremakemore
buymoremakemore Apr. 1 at 6:22 PM
$FBIO $DERM thank god. FinSun finally blocked me. Such a loser. Couldn’t even prove he made over 100k shorting these stocks
0 · Reply
FinSUN
FinSUN Apr. 1 at 6:09 PM
$DERM lets go to 4 now
0 · Reply
gb11
gb11 Mar. 31 at 8:05 PM
$DERM performed better today than $FBIO. But I wouldn't expect a recovery for $DERM until we close above 5.
0 · Reply
stklover
stklover Mar. 31 at 2:17 PM
$DERM After getting cloberred, my “3-day rule” applies, so I doubled my position on the stock this AM. I’m patient on this pig. Hoping some company just buys them out in the next year.
0 · Reply
FinSUN
FinSUN Mar. 31 at 11:04 AM
0 · Reply
pandodark
pandodark Mar. 31 at 3:51 AM
$DERM Management’s a joke. They probably won’t even issue news until it’s $2. Honestly, they are too old to see how the news and social cycle affects share price. They cost investors so much money …
0 · Reply
FinSUN
FinSUN Mar. 30 at 8:25 PM
1 · Reply
gb11
gb11 Mar. 30 at 8:23 PM
$DERM will the good new for $FBIO help this stock SP?
0 · Reply
FinSUN
FinSUN Mar. 30 at 2:23 PM
0 · Reply
FinSUN
FinSUN Mar. 30 at 2:00 PM
$DERM very bad
0 · Reply
T_rader
T_rader Mar. 30 at 1:41 PM
$DERM this seems to be a falling knife scenario, waiting patiently from the sidelines. Doesn’t seem to have any short term catalysts to get it kickstarted. Anyone see anything I don’t?
3 · Reply
ChartingMasters
ChartingMasters Mar. 30 at 8:23 AM
0 · Reply
OwlKing
OwlKing Mar. 29 at 8:30 PM
0 · Reply
MightyPumperDuck
MightyPumperDuck Mar. 29 at 12:43 PM
$DERM Pretty obvious, but a little something I needed to be reminded of. As the HCP's start taking hold, it's going to take some time, the coupons are going to come and go along the way. There will always be those that can't afford their medicine. Because HCP's are slow to get on board, the Coupons are front and center and take the Lions share of Scripts at the moment. I would expect Coupons to ebb and flow and even increase from time to time. This helps me to see that this 'Journey' with DERM is not going to be quick. The Coupons are going to be in the front seat of this 'Journey' for a bit. The company is benefitting, just not as fast as I wanted. I'm not going to predict a price today. But, I do believe wehave rhe bottom in and the SP will most likely be a double by end of year. I'm mildly pumping now; This company has an FDA approbed product that is 40% better than the current SOC Oracea. Time, it's just going to take time. Cont:.....
1 · Reply
gb11
gb11 Mar. 28 at 7:15 PM
$DERM only if they had provided guidance for 2026 it wouldn't have been such a bloodbath. Now bag holding with average around 6.1. Why didn't they provided a guidance to ease off concerns?
1 · Reply
StockBodega
StockBodega Mar. 28 at 4:47 PM
$FBIO $FBIOP $DERM Interesting they lower from buy to hold on the weekend before earnings come out..... Shorts are getting nervous!!
1 · Reply
buymoremakemore
buymoremakemore Mar. 27 at 11:05 PM
$DERM Even if most people have to try doxy before trying Emrosi for coverage once we are on more formularies, thats still going to be great revenue down the road. This isnt all or nothing for insurance to just cover Emrosi. With a drug getting such good feedback, the barrier to coverage is less painful. This is a game of patience. Dermatologists are fans and can see the results from their patients and from research and will keep prescribing regardless of subsidized coupons. So even if we got half the current prescription demand 80% revenue covered by insurance, thats still 15M a quarter. 2039 a long time of patent protection to make serious money! Most people are slowly learning about Emrosi. And they dont realize that they will have to keep taking it, but it is safe. The knowledge gap between patient and prescriber will narrow. And demand will grow in pace with revenue. Load up!
0 · Reply
MightyPumperDuck
MightyPumperDuck Mar. 27 at 9:18 PM
$DERM "February was a short month"...... that was a grasping for straws moment not a 'Take the bull by the Horns moment. Its still 90 days in Q1. Q2 has 91 days so its not really a thing. I can hang with the insurance deductables being eaten up to start the new year, but that was last year. I think he was embarrassed for the low realized pay per script. I'm going to summize that there was some biscuit chewing going on with his team. 'Get those HCP's on board!!!'. Did you hear it? I heard it. Bought a sizable grip this morning in the $4.60-1 range. Was looking for the retest of $4.51 but thought better of it. I believe the bottom is in. Also, the DOW did a nose dive into an empty pool today. That factors in as well. I may be a "PumperDuck", but I'm not blind. DERM will be SOC by end of next year and the payouts will be sizably larger. Sadly, the SP is most likely going to take to end of year to get where it SHOULD have been this week. $10-$12. Im expecting a small bounce next week.
1 · Reply
buymoremakemore
buymoremakemore Mar. 27 at 6:10 PM
$DERM It's green
1 · Reply
Hazzzzy
Hazzzzy Mar. 27 at 5:18 PM
$DERM Partly attributing slower uptake in Q1 to having “less days in February” is an interesting take. No position, but I do think Emrosi has some good potential.
2 · Reply